The brokerage said the opportunity for Ozempic (Semaglutide), a prescription injection for adults with Type 2 diabetes, in Canada is likely to be lower than earlier expectations.
Recent Posts
- Companies Ditching Quarterly Reports May Hit Valuations And Spark Sell-Offs, Warns Strategist— ‘Need More…Not Less’
- Western Union Likely To Report Lower Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
- HCA Healthcare Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
- Top Wall Street Forecasters Revamp Norfolk Southern Expectations Ahead Of Q1 Earnings
- Charter Communications Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts